Northwest Biotherapeutics Inc (NASDAQ:NWBO) a biotechnology company developing DCVax personalized immune therapies for solid tumour cancers, has received approval from the Paul Ehrlich Institute (PEI- the FDA of Germany) of a “Hospital Exemption” early access programme under Section 4b of the German Drug Law. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) stock performance was 16.93% in last session and finished the day at $9.18. Traded volume was 8,391,894 million shares in the last session and the average volume of the stock remained 992.28million shares. The beta of the stock remained 2.83. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) insider ownership is 9.86%.

Shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) zoomed 65 percent Tuesday after the company reported positive results in a trial of its kidney disease drug. La Jolla Pharmaceutical Company (NASDAQ:LJPC) rose 64.77 percent to $17.96 yesterday on volume of 8.33 million shares. The intra-day range of the stock was $17.25 to $19.50. La Jolla Pharmaceutical Company (NASDAQ:LJPC) has a market capitalization of $79.10 million.

OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced positive results from a randomized Phase 2 clinical trial evaluating Avastin® (bevacizumab) with or without ZYBRESTAT® (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. OXiGENE Inc (NASDAQ:OXGN)’s stock on Mar 11, 2014 reported an increase of 17.48% to the closing price of $2.42. Its fifty two weeks range is $1.96 -$4.95. The total market capitalization recorded $27.75 million. The overall volume in the last trading session was 6,334,713 million shares. In its share capital, OXiGENE Inc (NASDAQ:OXGN) has 2.64 million outstanding shares.

Tengion, Inc. (OTCMKTS:TNGN) issued notices (the “Notices”) to the holders (the “2012 Investors”) of senior secured notes issued on October 2, 2012 and to the holders (the “2013 Investors” and together with the 2012 Investors, the “Investors” and each, an “Investor”) of senior secured notes issued on June 28, 2013 stating that the Company plans to issue shares of common stock (the “Shares”), $0.001 par value per share (the “Common Stock”), or warrants to purchase Common Stock for nominal consideration (the “Warrants”), to the 2012 Investors in satisfaction of $354,071.43 in interest payments and to the 2013 Investors in satisfaction of $438,033.55, each due on April 1, 2014. On Tuesday, shares of Tengion, Inc. (OTCMKTS:TNGN) advanced 2.19% to close the day at $ 0.233. Company return on investment (ROI) is -196.08 % and its monthly performance is recorded as 5.91%. Tengion, Inc. (OTCMKTS:TNGN) quarterly revenue growth is -22.33%.